The Effects of Price Regulation on Pharmaceutical Expenditure and Availability
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to look for a different version below or search for a different version of it.
Other versions of this item:
- Kortelainen, Mika & Markkanen, Jaakko & Siikanen, Markku & Toivanen, Otto, 2023. "The Effects of Price Regulation on Pharmaceutical Expenditure and Availability," Working Papers 157, VATT Institute for Economic Research.
References listed on IDEAS
- Amanda Starc & Ashley Swanson, 2021. "Preferred Pharmacy Networks and Drug Costs," American Economic Journal: Economic Policy, American Economic Association, vol. 13(3), pages 406-446, August.
- Mark Duggan & Fiona Scott Morton, 2010.
"The Effect of Medicare Part D on Pharmaceutical Prices and Utilization,"
American Economic Review, American Economic Association, vol. 100(1), pages 590-607, March.
- Mark Duggan & Fiona Scott Morton, 2008. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization," NBER Working Papers 13917, National Bureau of Economic Research, Inc.
- H. E. Frech, III & Mark V. Pauly & William S. Comanor & Joseph R. Martinez, 2023. "Pharmaceutical Pricing and R&D as a Global Public Good," NBER Working Papers 31272, National Bureau of Economic Research, Inc.
- Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015.
"Market size and pharmaceutical innovation,"
RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
- Seabright, Paul & Scott Morton, Fiona & Dubois, Pierre & de Mouzon, Olivier, 2011. "Market Size and Pharmaceutical Innovation," CEPR Discussion Papers 8367, C.E.P.R. Discussion Papers.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," TSE Working Papers 11-232, Toulouse School of Economics (TSE), revised Mar 2014.
- Dubois, Pierre & Lasio, Laura, 2014.
"Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals,"
IDEI Working Papers
823, Institut d'Économie Industrielle (IDEI), Toulouse.
- Dubois, Pierre & Lasio, Laura, 2014. "Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals," CEPR Discussion Papers 9881, C.E.P.R. Discussion Papers.
- Dubois, Pierre & Lasio, Laura, 2014. "Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals," TSE Working Papers 14-471, Toulouse School of Economics (TSE), revised Mar 2018.
- Ornaghi, Carmine, 2009. "Mergers and innovation in big pharma," International Journal of Industrial Organization, Elsevier, vol. 27(1), pages 70-79, January.
- Josh Feng & Thomas Hwang & Luca Maini, 2023. "Profiting from Most-Favored-Customer Procurement Rules: Evidence from Medicaid," American Economic Journal: Economic Policy, American Economic Association, vol. 15(2), pages 166-197, May.
- Mats A. Bergman & David Granlund & Niklas Rudholm, 2016. "Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose," International Journal of Health Economics and Management, Springer, vol. 16(3), pages 201-214, September.
- Ali Yurukoglu & Eli Liebman & David B. Ridley, 2017.
"The Role of Government Reimbursement in Drug Shortages,"
American Economic Journal: Economic Policy, American Economic Association, vol. 9(2), pages 348-382, May.
- Ali Yurukoglu & Eli Liebman & David B. Ridley, 2012. "The Role of Government Reimbursement in Drug Shortages," NBER Working Papers 17987, National Bureau of Economic Research, Inc.
- Brekke, Kurt R. & Grasdal, Astrid L. & Holms, Tor Helge, 2009.
"Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?,"
European Economic Review, Elsevier, vol. 53(2), pages 170-185, February.
- Brekke, Kurt R. & Grasdal, Astrid L. & Holmås, Tor Helge, 2006. "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?," Working Papers in Economics 14/06, University of Bergen, Department of Economics.
- Kurt R. Brekke & Astrid L. Grasdal & Tor Helge Holmås, 2007. "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?," CESifo Working Paper Series 2059, CESifo.
- Nina Pavcnik, 2002. "Do Pharmaceutical Prices Respond to Potential Patient Out-of-Pocket Expenses?," RAND Journal of Economics, The RAND Corporation, vol. 33(3), pages 469-487, Autumn.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Pierre Dubois & Ashvin Gandhi & Shoshana Vasserman, 2022.
"Bargaining and International Reference Pricing in the Pharmaceutical Industry,"
NBER Working Papers
30053, National Bureau of Economic Research, Inc.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," Research Papers 3889, Stanford University, Graduate School of Business.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," CEPR Discussion Papers 17293, C.E.P.R. Discussion Papers.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 22-1338, Toulouse School of Economics (TSE).
- David Roodman & James G. MacKinnon & Morten Ørregaard Nielsen & Matthew D. Webb, 2019.
"Fast and wild: Bootstrap inference in Stata using boottest,"
Stata Journal, StataCorp LP, vol. 19(1), pages 4-60, March.
- James G. MacKinnon & Morten Ørregaard Nielsen & David Roodman & Matthew D. Webb, 2018. "Fast and Wild: Bootstrap Inference in Stata Using boottest," CREATES Research Papers 2018-34, Department of Economics and Business Economics, Aarhus University.
- David Roodman & James G. MacKinnon & Matthew D. Webb & Morten Ø. Nielsen, 2018. "Fast And Wild: Bootstrap Inference In Stata Using Boottest," Working Paper 1406, Economics Department, Queen's University.
- Liran Einav & Amy Finkelstein & Heidi Williams, 2016.
"Paying on the Margin for Medical Care: Evidence from Breast Cancer Treatments,"
American Economic Journal: Economic Policy, American Economic Association, vol. 8(1), pages 52-79, February.
- Liran Einav & Amy Finkelstein & Heidi Williams, 2014. "Paying on the margin for medical care: Evidence from breast cancer treatments," Discussion Papers 13-034, Stanford Institute for Economic Policy Research.
- Liran Einav & Amy Finkelstein & Heidi Williams, 2014. "Paying on the Margin for Medical Care: Evidence from Breast Cancer Treatments," NBER Working Papers 20226, National Bureau of Economic Research, Inc.
- Pierre Dubois & Laura Lasio, 2018. "Identifying Industry Margins with Price Constraints: Structural Estimation on Pharmaceuticals," American Economic Review, American Economic Association, vol. 108(12), pages 3685-3724, December.
- Alisa Tazhitdinova & Gonzalo Vazquez-Bare, 2023. "Difference-in-Differences with Unequal Baseline Treatment Status," NBER Working Papers 31063, National Bureau of Economic Research, Inc.
- Alpert, Abby, 2016. "The anticipatory effects of Medicare Part D on drug utilization," Journal of Health Economics, Elsevier, vol. 49(C), pages 28-45.
- Gary Solon & Steven J. Haider & Jeffrey M. Wooldridge, 2015.
"What Are We Weighting For?,"
Journal of Human Resources, University of Wisconsin Press, vol. 50(2), pages 301-316.
- Gary Solon & Steven J. Haider & Jeffrey Wooldridge, 2013. "What Are We Weighting For?," NBER Working Papers 18859, National Bureau of Economic Research, Inc.
- Liran Einav & Amy Finkelstein & Maria Polyakova, 2018.
"Private Provision of Social Insurance: Drug-Specific Price Elasticities and Cost Sharing in Medicare Part D,"
American Economic Journal: Economic Policy, American Economic Association, vol. 10(3), pages 122-153, August.
- Liran Einav & Amy Finkelstein & Maria Polyakova, 2016. "Private Provision of Social Insurance: Drug-specific Price Elasticities and Cost Sharing in Medicare Part D," NBER Working Papers 22277, National Bureau of Economic Research, Inc.
- Darius N. Lakdawalla, 2018. "Economics of the Pharmaceutical Industry," Journal of Economic Literature, American Economic Association, vol. 56(2), pages 397-449, June.
- Callaway, Brantly & Sant’Anna, Pedro H.C., 2021.
"Difference-in-Differences with multiple time periods,"
Journal of Econometrics, Elsevier, vol. 225(2), pages 200-230.
- Brantly Callaway & Pedro H. C. Sant'Anna, 2018. "Difference-in-Differences with Multiple Time Periods," Papers 1803.09015, arXiv.org, revised Dec 2020.
- Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-357, October.
- Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Dubois, Pierre & Majewska, Gosia, 2022.
"Mergers and Advertising in the Pharmaceutical Industry,"
TSE Working Papers
22-1380, Toulouse School of Economics (TSE).
- Dubois, Pierre & Majewska, Gosia, 2022. "Mergers and Advertising in the Pharmaceutical Industry," CEPR Discussion Papers 17658, C.E.P.R. Discussion Papers.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022.
"Bargaining and International Reference Pricing in the Pharmaceutical Industry,"
Research Papers
3889, Stanford University, Graduate School of Business.
- Pierre Dubois & Ashvin Gandhi & Shoshana Vasserman, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," NBER Working Papers 30053, National Bureau of Economic Research, Inc.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 22-1338, Toulouse School of Economics (TSE).
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," CEPR Discussion Papers 17293, C.E.P.R. Discussion Papers.
- Geng, Hao & Shi, Ce Matthew, 2024. "Health policy, price regulation, and innovation: Evidence from China’s vaccine industry," Journal of Development Economics, Elsevier, vol. 167(C).
- Pierre Dubois & Morten Sæthre, 2020.
"On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector,"
Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
- Dubois, Pierre & Sæthre, Morten, 2017. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Discussion Paper Series in Economics 3/2018, Norwegian School of Economics, Department of Economics.
- Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Post-Print hal-03176406, HAL.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," TSE Working Papers 18-883, Toulouse School of Economics (TSE), revised Mar 2020.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
- Fiona M. Scott Morton & Ariel Dora Stern & Scott Stern, 2018. "The Impact of the Entry of Biosimilars: Evidence from Europe," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 173-210, August.
- Atal, Juan Pablo & Cuesta, José Ignacio & Sæthre, Morten, 2018.
"Quality Regulation and Competition: Evidence from Pharmaceutical Markets,"
Discussion Paper Series in Economics
20/2018, Norwegian School of Economics, Department of Economics.
- Jesus Juan Pablo Atal & Jose´ Ignacio Cuesta & Morten Sæthre, 2019. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," PIER Working Paper Archive 19-017, Penn Institute for Economic Research, Department of Economics, University of Pennsylvania.
- Juan Pablo Atal & José Ignacio Cuesta & Morten Sæthre, 2022. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," NBER Working Papers 30325, National Bureau of Economic Research, Inc.
- Atal, Juan Pablo & Cuesta, Jose Ignacio & Sæthre, Morten, 2018. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," Research Department working papers 1211, CAF Development Bank Of Latinamerica.
- Aljoscha Janssen, 2022. "Price dynamics of Swedish pharmaceuticals," Quantitative Marketing and Economics (QME), Springer, vol. 20(4), pages 313-351, December.
- Hermosilla, Manuel, 2024. "Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D," Journal of Health Economics, Elsevier, vol. 94(C).
- Zhang, Xuan & Nie, Huihua, 2021. "Public health insurance and pharmaceutical innovation: Evidence from China," Journal of Development Economics, Elsevier, vol. 148(C).
- Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015.
"Market size and pharmaceutical innovation,"
RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
- Seabright, Paul & Scott Morton, Fiona & Dubois, Pierre & de Mouzon, Olivier, 2011. "Market Size and Pharmaceutical Innovation," CEPR Discussion Papers 8367, C.E.P.R. Discussion Papers.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," TSE Working Papers 11-232, Toulouse School of Economics (TSE), revised Mar 2014.
- Blume-Kohout, Margaret E. & Sood, Neeraj, 2013. "Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development," Journal of Public Economics, Elsevier, vol. 97(C), pages 327-336.
- Juan Pablo Atal & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2024.
"The Economics of the Public Option: Evidence from Local Pharmaceutical Markets,"
American Economic Review, American Economic Association, vol. 114(3), pages 615-644, March.
- Juan Pablo Atal & Jose Ignacio Cuesta & Felipe Gonzalez & Cristobal Otero, 2021. "The Economics of the Public Option:Evidence from Local Pharmaceutical Markets," PIER Working Paper Archive 21-012, Penn Institute for Economic Research, Department of Economics, University of Pennsylvania.
- Juan Pablo Atal & Jose Ignacio Cuesta & Felipe Gonzalez & Cristobal Otero, 2023. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," Working Papers 951, Queen Mary University of London, School of Economics and Finance.
- Juan Pablo Atala & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2021. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," Documentos de Trabajo 561, Instituto de Economia. Pontificia Universidad Católica de Chile..
- Juan Pablo Atal & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2022. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," NBER Working Papers 30779, National Bureau of Economic Research, Inc.
- Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
- Heidi L. Williams, 2016.
"Intellectual Property Rights and Innovation: Evidence from Health Care Markets,"
Innovation Policy and the Economy, University of Chicago Press, vol. 16(1), pages 53-87.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Chapters, in: Innovation Policy and the Economy, Volume 16, pages 53-87, National Bureau of Economic Research, Inc.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Working Papers 21246, National Bureau of Economic Research, Inc.
- Fabian Gaessler & Stefan Wagner, 2022.
"Patents, Data Exclusivity, and the Development of New Drugs,"
The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
- Gaessler, Fabian & Wagner, Stefan, 2019. "Patents, Data Exclusivity, and the Development of New Drugs," Rationality and Competition Discussion Paper Series 176, CRC TRR 190 Rationality and Competition.
- Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016.
"Patents and the Global Diffusion of New Drugs,"
American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
- Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2014. "Patents and the Global Diffusion of New Drugs," NBER Working Papers 20492, National Bureau of Economic Research, Inc.
- Iain Cockburn & Jean O. Lanjouw & Mark Schankerman, 2014. "Patents and the Global Diffusion of New Drugs," CEP Discussion Papers dp1298, Centre for Economic Performance, LSE.
- Cockburn, Iain & Lanjouw, Jean O. & Schankerman, Mark, 2016. "Patents and the global diffusion of new drugs," LSE Research Online Documents on Economics 65415, London School of Economics and Political Science, LSE Library.
- Cockburn, Iain & Lanjouw, Jean O. & Schankerman, Mark, 2014. "Patents and the global diffusion of new drugs," LSE Research Online Documents on Economics 60450, London School of Economics and Political Science, LSE Library.
- Schankerman, Mark & Cockburn, Iain M & Lanjouw, Jean, 2014. "Patents and the Global Diffusion of New Drugs," CEPR Discussion Papers 10149, C.E.P.R. Discussion Papers.
- Iizuka, Toshiaki & Uchida, Gyo, 2017.
"Promoting innovation in small markets: Evidence from the market for rare and intractable diseases,"
Journal of Health Economics, Elsevier, vol. 54(C), pages 56-65.
- IIZUKA Toshiaki & UCHIDA Gyo, 2016. "Promoting Innovation in Small Markets: Evidence from the market for rare and intractable diseases," Discussion papers 16036, Research Institute of Economy, Trade and Industry (RIETI).
- Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011.
"Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment,"
Journal of Public Economics, Elsevier, vol. 95(7), pages 624-638.
- Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7-8), pages 624-638, August.
- Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2010. "Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment," CESifo Working Paper Series 3258, CESifo.
- Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2014.
"Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark,"
Journal of Health Economics, Elsevier, vol. 36(C), pages 174-187.
- Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas, 2010. "Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark," ZEW Discussion Papers 10-062, ZEW - Leibniz Centre for European Economic Research.
- Ulrich Kaiser & Susan J. Mendez & Thomas Rønde, 2010. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," CIE Discussion Papers 2010-01, University of Copenhagen. Department of Economics. Centre for Industrial Economics.
- Ulrich Kaiser & Susan J. Méndez & Thomas Rønde & Hannes Ullrich, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," Working Papers 330, University of Zurich, Department of Business Administration (IBW).
- Kaiser, Ulrich & Méndez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," IZA Discussion Papers 7248, Institute of Labor Economics (IZA).
- Kaiser, Ulrich & Méndez, Susan & Rønde, Thomas & Ullrich, Hannes, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," VfS Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 79937, Verein für Socialpolitik / German Economic Association.
- Beth Woods & James Lomas & Mark Sculpher & Helen Weatherly & Karl Claxton, 2024. "Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 804-819, April.
More about this item
Keywords
pharmaceutical expenditure; pharmaceutical pricing; generic competition; reference pricing; Regulation;All these keywords.
JEL classification:
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
- L51 - Industrial Organization - - Regulation and Industrial Policy - - - Economics of Regulation
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
- C23 - Mathematical and Quantitative Methods - - Single Equation Models; Single Variables - - - Models with Panel Data; Spatio-temporal Models
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cpr:ceprdp:18497. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://www.cepr.org .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.